IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. The company was formerly known as Century Park Pictures Corporation and changed its name to IsoRay, Inc. in 2005. IsoRay, Inc. was founded in 1983 and is based in Richland, Washington.
Industry, Sector and Symbol
Stock Exchange NYSEAMERICAN
Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:ISR
CUSIPN/A
Phone+1-509-3751202
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-95.25%
Return on Equity-69.11%
Return on Assets-58.22%
Miscellaneous
EmployeesN/A
Outstanding Shares55,100,000
Market Cap$24.87
IsoRay (NYSEAMERICAN:ISR) Frequently Asked Questions
What is IsoRay's stock symbol?
IsoRay trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ISR."
How were IsoRay's earnings last quarter?
IsoRay, Inc. (NYSEAMERICAN:ISR) announced its quarterly earnings data on Thursday, May, 3rd. The healthcare company reported ($0.02) EPS for the quarter, topping the Zacks' consensus estimate of ($0.03) by $0.01. The healthcare company had revenue of $1.57 million for the quarter. IsoRay had a negative return on equity of 69.11% and a negative net margin of 95.25%. View IsoRay's Earnings History.
When is IsoRay's next earnings date?
What price target have analysts set for ISR?
2 Wall Street analysts have issued twelve-month price objectives for IsoRay's stock. Their forecasts range from $1.00 to $2.00. On average, they anticipate IsoRay's share price to reach $1.50 in the next twelve months. This suggests a possible upside of 154.2% from the stock's current price. View Analyst Ratings for IsoRay.
What is the consensus analysts' recommendation for IsoRay?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IsoRay in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Are investors shorting IsoRay?
IsoRay saw a increase in short interest in the month of June. As of June 29th, there was short interest totalling 95,615 shares, an increase of 181.9% from the June 15th total of 33,924 shares. Based on an average trading volume of 112,686 shares, the days-to-cover ratio is currently 0.8 days. Currently, 0.2% of the shares of the company are short sold. View IsoRay's Current Options Chain.
Who are some of IsoRay's key competitors?
Some companies that are related to IsoRay include Bovie Medical (BVX), InfuSystem (INFU), Retractable Technologies (RVP), Milestone Scientific (MLSS), Akers Biosciences (AKR), Daxor (DXR), Omega Diagnostics Group (ODX), Relevium Technologies (RLV), Vigil Health Solutions (VGL), Iris Biotechnologies (IRSB), SECTOR 10 (SECI), Lifestyle Delivery Systems (LDSYF) and RESMED/IDR UNRESTR (RMD).
Who are IsoRay's key executives?
IsoRay's management team includes the folowing people:
- Mr. William Cavanagh III, COO & Chief Scientific Officer (Age 52)
- Mr. Michael L. Krachon, VP of Sales & Marketing (Age 47)
- Ms. Lori A. Holmes-Woods, Interim Chief Exec. Officer (Age 56)
- Mr. Mark Austin CPA, Principal Accounting & Financial Officer and Controller (Age 31)
- Mrs. Jennifer Streeter, VP of HR (Age 48)
Has IsoRay been receiving favorable news coverage?
News stories about ISR stock have trended positive recently, according to Accern. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. IsoRay earned a news sentiment score of 0.43 on Accern's scale. They also assigned news articles about the healthcare company an impact score of 47.48 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
How do I buy shares of IsoRay?
Shares of ISR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is IsoRay's stock price today?
One share of ISR stock can currently be purchased for approximately $0.59.
How big of a company is IsoRay?
IsoRay has a market capitalization of $24.87 million.
How can I contact IsoRay?
IsoRay's mailing address is 350 Hills St Ste 106, RICHLAND, WA 99354-5511, United States. The healthcare company can be reached via phone at +1-509-3751202.
MarketBeat Community Rating for IsoRay (NYSEAMERICAN ISR)
MarketBeat's community ratings are surveys of what our community members think about IsoRay and other stocks. Vote "Outperform" if you believe ISR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ISR will underperform the S&P 500 over the long term. You may vote once every thirty days.
